- Case report
- Open Access
- Open Peer Review
Combined adenocarcinoid and mucinous cystadenoma of the appendix: a case report
© Velusamy et al; licensee BioMed Central Ltd. 2009
- Received: 21 February 2008
- Accepted: 26 January 2009
- Published: 26 January 2009
Adenocarcinoid of the appendix is a rare malignant tumour with features of both adenocarcinoma and carcinoid, showing both epithelial and endocrine differentiation. Mucinous cystadenoma is the commonest of the benign neoplasms of the appendix, with an incidence of 0.6% in appendicectomy specimens. We report a rare combination of these tumours and discuss the latest treatment options. To the best of our knowledge, only six cases have been reported in the literature to date.
A 71-year-old Caucasian man presented to our department with a right iliac fossa mass associated with pain. Laparoscopy revealed an adenocarcinoid of the appendix in combination with mucinous cystadenoma. He underwent a radical right hemicolectomy with clear margins and lymph nodes.
Adenocarcinoids account for 2% of primary appendiceal malignancies. Most tumours are less than 2 cm in diameter and 20% of them metastasize to the ovaries. The mean age for presentation is 59 years and the 5-year survival rate ranges from 60% to 84%. Right hemicolectomy is generally advised if any of the following features are present: tumours greater than 2 cm, involvement of resection margins, greater than 2 mitoses/10 high-power fields on histology, extension of tumour beyond serosa. Chemotherapy mostly with 5-Fluorouracil and Leucovorin is advised for remnant disease after surgery. Cytoreductive surgery with intraperitoneal chemotherapy can offer improved survival for advanced peritoneal dissemination.
- Carcinoid Tumour
- Laparoscopic Appendicectomy
- Intraperitoneal Chemotherapy
- Benign Neoplasm
- Pseudomyxoma Peritonei
Mucinous cystadenoma is the commonest of the benign neoplasms of the appendix, with an incidence of 0.6% in appendicectomy specimens . Adenocarcinoid is a rare but well recognised tumour of the appendix which exhibits features of both carcinoid and adenocarcinoma. We report a patient with combined adenocarcinoid and mucinous cystadenoma of the appendix. To the best of our knowledge, only six cases have been reported in the literature to date [2, 3].
Adenocarcinoid is recognised as a tumour which has features of both adenocarcinoma and carcinoid, first described by Gagne et al. in 1969 . It is widely known by different names such as goblet cell carcinoid , crypt cell carcinoid, and amphicrine cell carcinoma. There is still debate about the origin of this tumour and several hypotheses exist, hence the various nomenclature. Adenocarcinoma arises from primordial endodermal elements while carcinoid arises from neural crest cells. Some authors suggest that goblet cell carcinoids arise from a pluripotent cell with divergent neuroendocrine and mucinous differentiation .
Mucinous cystadenoma is rare but is the commonest of the benign appendiceal tumours. It can present as appendicitis, mucocele or if the tumour ruptures, as pseudomyxoma peritonei. Treatment is usually appendicectomy with care taken not to spill the mucin intraperitoneally.
Adenocarcinoids account for 2% of primary appendiceal malignancies. Most tumours are less than 2 cm in diameter and 20% of them metastasize to the ovaries . The mean age at presentation is 59 years and the 5-year survival rate ranges from 60% to 84% . The tumour usually spares the mucosa, infiltrates muscularis propria and peri-appendiceal fat and can stain positively for mucin, CEA, cytokeratin, lysozyme, chromogranin A, serotonin and synaptophysin. Goblet cell carcinoids have increased expression of NAP1L1, MAGE-D2, and MTA-1 genes compared with benign carcinoids. Ki 67 is a tumour marker which is expressed in higher levels in metastatic adenocarcinoids compared to localized ones. This can be useful in predicting tumour behaviour and subsequent surgical management . Recent studies suggest that goblet cell carcinoids have biological and immunohistochemical profiles more similar to adenocarcinoma than to classical carcinoids which may explain their more aggressive behaviour and therefore substantiate more extensive treatment [10, 11].
There is ongoing surgical controversy as to whether appendicectomy or right hemicolectomy is necessary for appendiceal carcinoid tumours. For classical carcinoid tumours, most centres consider tumour size to be the main discretionary factor. Those <2 cm are usually treated with appendicectomy alone. For adenocarcinoids, right hemicolectomy is generally advised if any of the following features are present: tumours greater than 2 cm, involvement of resected margins, greater than 2 mitoses/10 high-power fields (hpf), extension of tumour beyond serosa, lymphovascular invasion or lymph node metastases [12, 13]. Some authors recommend right hemicolectomy for adenocarcinoids of any size due to their propensity to metastasize , while others use similar determinative histological criteria as those for classical carcinoids to plan treatment . A meta-analysis of retrospective chart reviews by Varisco et al. evaluated the efficacy of appendicectomy versus hemicolectomy for localized adenocarcinoids. Their analysis suggests appendicectomy alone has a role in the treatment of localized tumours. However, in the presence of unfavourable features including moderate to severe atypia, involvement of caecum, and more than 2 mitoses per hpf, they recommend an interval hemicolectomy .
Chemotherapy mostly with 5-Fluorouracil and Leucovorin is advised for remnant disease after surgery. Cytoreductive surgery with intraperitoneal chemotherapy can offer improved survival for advanced peritoneal dissemination . In female patients regardless of age, bilateral salpingo-oopherectomy is advocated, as there is a significant risk of ovarian involvement. Irrespective of the type of surgical intervention, all patients warrant lifelong colonoscopic surveillance.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Marudhanayagam R, Williams GT, Rees BI: Review of the pathological results of 2660 appendicectomy specimens. J Gastroenterol. 2006, 41 (8): 745-749. 10.1007/s00535-006-1855-5.View ArticleGoogle Scholar
- Al-Talib RK, Mason CH, Theaker CJ: Combined goblet cell carcinoid and mucinous cystadenoma of the appendix. J Clin Pathol. 1995, 48: 869-870. 10.1136/jcp.48.9.869.View ArticlePubMedPubMed CentralGoogle Scholar
- Carr NJ, Remotti H, Sobin LH: Dual carcinoid/epithelial neoplasia of the appendix. Histopathology. 1995, 27 (6): 557-562. 10.1111/j.1365-2559.1995.tb00327.x.View ArticlePubMedGoogle Scholar
- Gagne F, Fortin P, Dufour V, Delage C: Tumeurs de l'appendice associant de carreteres histologique de carcinoide et d'adenocarcinome. Ann Anat Pathol. 1969, 14: 393-406.Google Scholar
- Subbuswamy SG, Gibb NM, Ross CF, Morson BC: Goblet cell carcinoid of the appendix. Cancer. 1974, 34: 338-344. 10.1002/1097-0142(197408)34:2<338::AID-CNCR2820340218>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Kanthan R, Saxena A, Kanthan SC: Goblet cell carcinoids of the appendix: immunophenotype and ultrastructural study. Arch Path Lab Med. 2001, 125: 386-390.PubMedGoogle Scholar
- Staley CA: Primary appendiceal malignancies. Oxford Textbook of Surgery. Edited by: Morris PJ, Wood WC. 2000, New York: Oxford University Press, section 27.2: 1545-1548. 2Google Scholar
- Pahalavan PS, Kanthan R: Goblet cell carcinoid of the appendix. World J Surg Oncol. 2005, 3: 366-Google Scholar
- Modlin IM, Kidd M, Latich I, Zikusoka MN, Eick GN, Mane SM, Camp RL: Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann Surg. 2006, 244 (1): 52-60. 10.1097/01.sla.0000217617.06782.d5.View ArticlePubMedPubMed CentralGoogle Scholar
- van Eeden S, Offerhaus GJ, Hart AA, Boerrigter L, Nederlof P, Porter E, van Velthuysen M-LF: Goblet cell carcinoid of the appendix: a specific type of carcinoma. Histopathology. 2007, 51 (6): 763-773. 10.1111/j.1365-2559.2007.02883.x.View ArticlePubMedGoogle Scholar
- Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol. 2007, 18 (1): 16-22. 10.1007/s12022-007-0004-x.View ArticlePubMedGoogle Scholar
- Fornaro R, Frascio M, Sticchi C, De Salvo L, Stabilini C, Mandolfino F, Ricci B, Gianetta E: Appendectomy or right hemicolectomy in the treatment of appendiceal carcinoid tumours?. Tumori. 2007, 93 (6): 587-590.PubMedGoogle Scholar
- Bucher P, Gervaz P, Ris F, Oulhaci W, Egger JF, Moerel P: Surgical treatment of appendiceal adenocarcinoid. World J Surg. 2005, 29 (11): 1436-1439. 10.1007/s00268-005-7958-y.View ArticlePubMedGoogle Scholar
- Varisco B, McAlvin B, Dias J, Franga D: Adenocarcinoid of the appendix: is right hemicolectomy necessary? A meta-analysis of retrospective chart reviews. Am Surg. 2004, 70 (7): 593-599.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.